Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
PLoS One. 2020 Dec 23;15(12):e0242710. doi: 10.1371/journal.pone.0242710. eCollection 2020.
The use of patient-reported outcomes (PROs) to systematically quantify adverse events (AE) will assist in the improvement of medical care and the QoL of patients living with HIV (PLWH). The aim of this study was to investigate the associations between self-reported side effects and other PROs, demographics and laboratory data, and further evaluate the Health Questionnaire (HQ) as a tool for following trends in patient-reported side effects over time in relation to trends in prescribed third agent in ART.
The Swedish National Registry InfCareHiv includes an annual self-reported nine-item HQwhich is used in patient-centered HIV care in all Swedish HIV units. In this study, the experience of side effects was addressed. We analyzed 9,476 HQs completed by 4,186 PLWH together with details about their prescribed ART and relevant biomarkers collected during 2011-2017. Data were analyzed using descriptive statistics, Pearson's correlation coefficient and mixed logistic regression.
The cross-sectional analysis of the HQs showed that the frequency of reported side effects decreased from 32% (2011) to 15% (2017). During the same period, there was a shift in ART prescription from efavirenz (EFV) to dolutegravir (DTG) (positive correlation coefficient r = 0.94, p = 0.0016). Further, PLWH who reported being satisfied with their physical health (OR: 0.47, p = <0.001) or psychological health (OR: 0.70, p = 0.001) were less likely to report side effects than those less satisfied.
Self-reported side effects were found to have a close relationship with the patient's ratings of their overall health situation and demonstrated a strong correlation with the sharp decline in use of EFV and rise in use of DTG, with reported side effects being halved. This study supports the feasibility of using the HQ as a tool for longitudinal follow up of trends in PROs.
使用患者报告的结局(PROs)系统地量化不良事件(AE)将有助于改善医疗保健并提高 HIV 感染者(PLWH)的生活质量(QoL)。本研究旨在探讨自我报告的副作用与其他 PROs、人口统计学和实验室数据之间的关系,并进一步评估健康问卷(HQ)作为一种工具,用于随着时间的推移,在与 ART 中规定的第三种药物的趋势相关的情况下,跟踪患者报告的副作用趋势。
瑞典国家登记处 InfCareHiv 包含一项年度自我报告的九项 HQ,该问卷用于所有瑞典 HIV 单位的以患者为中心的 HIV 护理。在本研究中,我们研究了副作用的发生情况。我们分析了 2011-2017 年间由 4186 名 PLWH 完成的 9476 份 HQ 以及与他们规定的 ART 和相关生物标志物相关的详细信息。使用描述性统计、Pearson 相关系数和混合逻辑回归分析数据。
HQ 的横断面分析显示,报告的副作用频率从 32%(2011 年)下降到 15%(2017 年)。在同一时期,ART 处方从依非韦伦(EFV)转向多替拉韦(DTG)(正相关系数 r = 0.94,p = 0.0016)。此外,报告对身体健康(OR:0.47,p <0.001)或心理健康(OR:0.70,p = 0.001)满意的 PLWH 报告副作用的可能性低于那些不太满意的人。
自我报告的副作用与患者对整体健康状况的评估密切相关,并与 EFV 使用急剧下降和 DTG 使用增加密切相关,报告的副作用减少了一半。这项研究支持使用 HQ 作为 PRO 趋势纵向随访的工具的可行性。